From: A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)
Magnitude of the adverse event
Mild adverse event. Asymptomatic or mild clinical symptoms or just an observation; intervention not indicated.
Moderate adverse event. Minimal, local or non-invasive intervention indicated.
Serious or medically significant adverse event, but not immediately life-threatening. Hospitalization or hospitalization prolongation indicated; important limitation of self-care.
Adverse event with risk of mortality or disability.
Death associated with an adverse event.